APAC IPOs & Placements

Zhen Zhou, Toh

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Sino Biopharmaceutical / Equity Capital Markets

<p>A shareholder of <a href="https://www.smartkarma.com/entities/sino-biopharmaceutical" target="_blank" data-smartkarma-citation="entities:230:1" rel="noopener">Sino Biopharmaceutical (1177 HK)</a> is looking to sell about US$297m worth of shares in an accelerated block trade.</p><p>In this note, we will look into who is the seller of the block and run the deal through our deal framework.</p>

A shareholder of Sino Biopharmaceutical (1177 HK) is looking to sell about US$297m worth of shares in an accelerated block trade.In this note, we will look into who is the seller of the block and run the deal through our deal framework.

Sino Biopharm (中国生物制药) Placement - Not a Big Deal, Still a Good Company but Relatively Expensive